Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02561312
Recruitment Status : Completed
First Posted : September 28, 2015
Last Update Posted : July 27, 2018
Sponsor:
Information provided by (Responsible Party):
Jennifer Keates, M.D., Chattanooga-Hamilton County Hospital Authority

Tracking Information
First Submitted Date September 23, 2015
First Posted Date September 28, 2015
Last Update Posted Date July 27, 2018
Actual Study Start Date September 2015
Actual Primary Completion Date September 30, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: September 24, 2015)
Hemoglobin S, baseline hemoglobin/hematocrit, [ Time Frame: Pre Infusion, lab collected monthly for one year thru study completion ]
Lab parameters pre-infusion for each method of transfusion
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: September 24, 2015)
Hemoglobin S, end of transfusion hemoglobin/hematocrit, blood volume, alloantibodies, [ Time Frame: Post Infusion, lab collected monthly for one year thru study completion ]
Lab parameters post-infusion for each method of transfusion
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures
 (submitted: September 24, 2015)
  • Nursing Time score [ Time Frame: Monthly at end of each transfusion for one year thru study completion ]
    Determine nursing time to administer straight versus manual exchange transfusion
  • Patient Satisfaction Questionnaire [ Time Frame: At end of 6 month period and at 12 months (after RMPET and ST) ]
    Patient satisfaction questionnaire consisting of 5 Likert scaled questions for preference of RMPET versus ST assessed after six months on either cohort
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Official Title Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Brief Summary Chronic blood transfusions are essential supportive care for sickle cell patients at high risk for morbidity and mortality due to stroke. These patients, however, are at risk for iron overload. In the investigator's comprehensive sickle cell center, the investigators support chronic transfusion with rapid manual partial exchange transfusions (RMPET) using a single access central line port. The investigators do not have a comprehensive adult sickle cell program but upon transition of patients the patients would be provided simple transfusion (ST) in an adult ambulatory infusion setting due to nursing acuity needed for RMPET. The investigators plan to study the institution's participants currently on chronic transfusion support and compare different transfusion modalities to better understand the effects from switching from RMPET to ST. To date, there are no such comparisons within and between sickle cell patients in the literature.
Detailed Description

II. Objective. Compare differences in RMPET versus ST.

III. Specific Aims:

  1. To compare key predictive hematologic factors (hematocrit, hemoglobin, hemoglobin S quantification, blood volume and alloantibodies) for relative risk of stroke utilizing two methods of blood transfusion therapy.
  2. To determine the nursing time to administer straight versus manual exchange transfusion therapy.
  3. To survey patient satisfaction for both procedures.

IV: Background/Significance:

Stroke occurs in 10% of Sickle Cell Disease (SCD) patients before the age of 20 Years. Current standard of care for secondary overt stroke prevention in patients with SCD is chronic red blood cell (RBC) transfusions. Stroke recurs in ~ 60% of patients without chronic RBC therapy and in ~ 20% of patients with chronic transfusion while maintaining a hemoglobin S percentage of less than 30%. Indefinite transfusion therapy is practiced as discontinuation after short-term or long-term prophylactic transfusions leads to recurrent overt strokes and more ensuing CNS damage, even with transition to hydroxyurea. Chronic transfusions also prevent initial stroke in high-risk patients identified by transcranial Doppler (TCD) ultrasound. The Stroke Prevention Study in Sickle Cell Disease (STOP) demonstrated a 92% stroke risk reduction among 63 of 130 children with abnormal TCD results. Rates of stroke declined significantly since implementing routine TCD screening and primary prophylactic transfusion therapy. The subsequent STOP 2 trial supports the use of chronic transfusion indefinitely because discontinuation resulted in an increased rate of abnormal TCD conversion and development of overt stroke. Discontinuing transfusions on the STOP 2 trial was also associated with a higher occurrence of silent cerebral infarcts, documented in 3 of 37 patients (8.1%) in the continued-transfusion group compared with 11 of 40 (27.5%) in the transfusion-halted group. More recent studies demonstrate that SCD patients are also at risk for silent cerebral infarcts. An association between worsening vasculopathy shown by magnetic resonance angiography and progressive overt and silent infarcts on magnetic resonance imaging has been found. More aggressive magnetic resonance imaging screening may be indicated and this could result in more patients with SCD treated with chronic transfusion.

Common chronic transfusion modalities include ST or RMPET. The goal of therapy is to reduce the hemoglobin S level either by diluting the blood (ST) or by removing and replacing the blood with non-sickle hemoglobin (RMPET). To prevent further brain injury, the goal of transfusion therapy is to lower the hemoglobin S quantification to less than 30% on a routine basis, usually monthly transfusion procedure. There are many large centers that utilize erythrocytapheresis which is considered the preferable method if available.

The investigator's study will focus on the types of RBC exchange therapy currently utilized in the investigator's Infusion Clinic at T.C. Thompson Children's Hospital. The investigators will determine which transfusion method is best for each participant for achieving the hematologic parameters of lower hemoglobin S quantification.The investigators will also measure the amount of nursing time for each procedure and which method is preferred by participants. The investigators will share the institutional observations with other institutions who may intend to switch between RMPET and ST.

V. Methods:

Study Design: Prospective observational cohort study

The investigators will utilize the institution's current population of 8 eligible chronically exchanged transfused participants at the T.C. Thompson Children's Infusion Clinic. The eligible participants will be invited to participate in a cross over design study so that each participant serves as its own control. Eight participants will be randomly assigned (blinded envelope) whereby four participants will start with rapid manual partial exchange transfusion: 3 months will be spent in a wash out period, then 3 months of data collection for RMPET. This group will then be switched to simple transfusion with a wash out period of three months, then data collection for three months. The second group of four participants will start with simple transfusion and have an identical study design over 12 months (3 months of collected data during simple transfusion, a 3 month wash out period, switch to rapid manual partial exchange transfusion for three months, then 3 months of data collection for RMPET).

The investigators will optimize all therapy to achieve the post transfusion goal of <30% hemoglobin S and post transfusion Hb <12g/DL.with each transfusion performed for best practice in avoiding sickle cell complications.

Study Type Observational
Study Design Observational Model: Case-Crossover
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population 8 chronically exchanged transfused participants at T.C. Thompson Children's Infusion Clinic with sickle cell disease (Hemoglobin SS or SBeta thalassemia) currently receiving rapid manual partial exchange transfusion.
Condition
  • Anemia, Sickle Cell
  • Sickling Disorder Due to Hemoglobin S
Intervention
  • Other: Rapid manual partial exchange transfusion
    The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
  • Other: Simple Transfusion
    The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
Study Groups/Cohorts
  • RMPET
    For rapid manual partial exchange transfusion, participants with a weight >50kg, 500 ml of whole blood is removed from the participant via a single lumen central venous line, followed by infusion of 500 ml of saline. A 30 second wait time is utilized for equilibration to occur. A second 500 ml aliquot is removed, and then two units of packed red blood cells (PRBC) are infused. (This is customized for a patient with large red blood cell mass). For participants <50 kg, the individual exchange aliquots are adjusted to 10 ml/kg or normal saline and PRBC.
    Intervention: Other: Rapid manual partial exchange transfusion
  • Simple Transfusion
    For simple transfusion, the volume of packed red blood cells (PRBC) to be transfused in the participant is 10-15 cc/kg. No normal saline exchange is required. All blood is transfused through a single lumen central venous line.
    Intervention: Other: Simple Transfusion
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: July 26, 2018)
9
Original Estimated Enrollment
 (submitted: September 24, 2015)
8
Actual Study Completion Date September 30, 2017
Actual Primary Completion Date September 30, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Participants between 3 and 25 years of age
  2. Diagnosis of Hemoglobin SS or SBeta thalassemia
  3. On chronic exchange for stroke prevention
  4. Performance status: Lansky play score of 100%, and if over 16 years of age, Karnofsky=100%

Exclusion Criteria:

  1. Participant has experienced more than one stroke and has a modified Rankin Scale of >3.
  2. Diagnosis of Hemoglobin SC disease
  3. Participants on chronic transfusion for priapism.
Sex/Gender
Sexes Eligible for Study: All
Ages 3 Years to 25 Years   (Child, Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT02561312
Other Study ID Numbers 15-084
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Jennifer Keates, M.D., Chattanooga-Hamilton County Hospital Authority
Study Sponsor Chattanooga-Hamilton County Hospital Authority
Collaborators Not Provided
Investigators
Principal Investigator: Jennifer Keates, MD Children's Hospital at Erlanger
PRS Account Chattanooga-Hamilton County Hospital Authority
Verification Date July 2018